医药行业月报：聚焦2025ASCO，国产新药再创历史.docx

]UK IBI363 PD-1/IL-2

IO?J/NSCLC

Oral

First-in-classPD-1/IL-2bispecificantibodyIBI363inpatients(Pts)withadvancedimmunotherapy-treatednon-smallcelllungcancer(NSCLC).

EfficacyandsafetyofIBI363monotherapyorincombination

]UK IBI363 PD-1/IL-2 MSSi*% I

Oral

Oral

withbevacizumabinpatientswithadvancedcolorectalcancer.

Amulticenter,randomized,controlled,open-label,phase2studyofthePD-1/IL-2o-biasbispecificantibodyfusionproteinIBI363inmucosalandacralmelanoma.

Claudinl8.2(CLDNI8.2)expressionandefficacyin

Oral pancreaticductaladenocarcinoma(PDAC):ResultsfromaphaseIdoseexpansioncohortevaluatingIBI343.

Efficacyofcontinuouszanubrutinibvsfixed-duration

venetoclaxincombinationwithobinutuzumabin

lLCLL

Oral

treatment-naive(TN)chroniclymphocyticleukemia(CLL):

Amatching-adjustedindirectcomparison(MAIC).

First-in-humanstudyofBG-C9074,aB7-H4-targetingADC

B?,ii$J1st BG-C9074 B7H4ADC Jfl IJ I Poster

Publication

inpatientswithadvancedsolidtumors:Preliminaryresultsofthedose-escalationphase.

PreliminaryresultsofZG005,abispecificantibody

(I1!lN ZG005 PD-1/TIGIT 2L*nI*.% I/II targetingPD-1andTIGIT,asmonotherapyinpatientswithOnly

DLL3/DLL3/

(I1!IU ZG006 3L+SCLC II

CD3

advancedcervicalcancer.

Aphase2doseexpansionstudyofZG006,atrispecificTOral cellengagertargetingCD3/DLL3/DLL3,asmonotherapyin

patientswithadvancedsmallcelllungcancer.

Phase1/2studiesofDZD8586inCLL/SLLpatientsafter

fi*YNDZD8586

fi*YN

DZD8586

BTK/Lyn

R/RCLL/SLL

I/II

*YXK

DZD8586

BTK/Lyn

R/RDLBCL

I/II

PublicationOnly

covalentornon-covalentBTKinhibitorsandBTi(degraders.

Phase2studyofDZD8586,anon-covalentBBBpenetrantLYN/BTi(dualinhibitor,asmonotherapyinrelapsed/refractorydiffuselargeB-celllymphoma(r/rDLBCL;TAI-SHAN9)

EGFR-TKIH]

fi*CX DZD6008 fiEGFR I/II PosterNSCLC

)S@% ICP-248 BCL-2 BiH